Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2017

01-03-2017 | Original Article

Multicompartment analysis of protein-restricted phenylketonuric mice reveals amino acid imbalances in brain

Authors: Kara R. Vogel, Erland Arning, Teodoro Bottiglieri, K. Michael Gibson

Published in: Journal of Inherited Metabolic Disease | Issue 2/2017

Login to get access

Abstract

Background

The mainstay of therapy for phenylketonuria (PKU) remains dietary protein restriction. Developmental and neurocognitive outcomes for patients, however, remain suboptimal. We tested the hypothesis that mice with PKU receiving protein-restricted diets would reveal disruptions of brain amino acids that shed light on these neurocognitive deficits.

Method

Phenylalanine hydroxylase-deficient (PKU) mice and parallel controls (both wild-type and heterozygous) were fed custom diets containing 18, 6, and 4 % protein for 3 weeks, after which tissues (brain, liver, sera) were collected for amino acid analysis profiling.

Results

Phenylalanine (phe) was increased in all tissues (p < 0.0001) of PKU mice and improved with protein restriction. In sera, decreased tyrosine (p < 0.01) was corrected (defined as not significantly different from the level in control mice receiving 18 % chow) with protein restriction, whereas protein restriction significantly increased many other amino acids. A similar trend for increased amino acid levels with protein restriction was also observed in liver. In brain, the effects of protein restriction on large neutral amino acids (LNAAs) were variable, with some deficit correction (threonine, methionine, glutamine) and no correction of tyrosine under any dietary paradigm. Protein restriction (4 % diet) in PKU mice significantly decreased lysine, arginine, taurine, glutamate, asparagine, and serine which had been comparable to control mice under 18 % protein intake.

Conclusion

Depletion of taurine, glutamate, and serine in the brain of PKU mice with dietary protein restriction may provide new insight into neurocognitive deficits of PKU.
Appendix
Available only for authorised users
Literature
go back to reference Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J, Moseley K, Suter R, van Calcar SC, Wiles J, Cederbaum S (2013) Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med 15(8):591–599CrossRefPubMedPubMedCentral Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J, Moseley K, Suter R, van Calcar SC, Wiles J, Cederbaum S (2013) Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med 15(8):591–599CrossRefPubMedPubMedCentral
go back to reference Giller K, Huebbe P, Hennig S, Dose J, Pallauf K, Doering F, Rimbach G (2013) Beneficial effects of a 6-month dietary restriction are time-dependently abolished within 2 weeks or 6 months of refeeding-genome-wide transcriptome analysis in mouse liver. Free Radic Biol Med 61:170–178CrossRefPubMed Giller K, Huebbe P, Hennig S, Dose J, Pallauf K, Doering F, Rimbach G (2013) Beneficial effects of a 6-month dietary restriction are time-dependently abolished within 2 weeks or 6 months of refeeding-genome-wide transcriptome analysis in mouse liver. Free Radic Biol Med 61:170–178CrossRefPubMed
go back to reference Glushakov AV, Glushakova O, Varshney M, Bajpai LK, Sumners C, Laipis PJ, Embury JE, Baker SP, Otero DH, Dennis DM, Seubert CN, Martynyuk AE (2005) Long-term changes in glutamatergic synaptic transmission in phenylketonuria. Brain 128(Pt 2):300–307PubMed Glushakov AV, Glushakova O, Varshney M, Bajpai LK, Sumners C, Laipis PJ, Embury JE, Baker SP, Otero DH, Dennis DM, Seubert CN, Martynyuk AE (2005) Long-term changes in glutamatergic synaptic transmission in phenylketonuria. Brain 128(Pt 2):300–307PubMed
go back to reference Gundersen V, Storm-Mathisen J, Bergersen LH (2015) Neuroglial transmission. Physiol Rev 95(3):695–726CrossRefPubMed Gundersen V, Storm-Mathisen J, Bergersen LH (2015) Neuroglial transmission. Physiol Rev 95(3):695–726CrossRefPubMed
go back to reference Liang L, Gu X, Li D, Lu L (2011) The expression and phosphorylation of acid sensing ion channel 1a in the brain of a mouse model of phenylketonuria. Int J Neurosci 121(7):399–404CrossRefPubMed Liang L, Gu X, Li D, Lu L (2011) The expression and phosphorylation of acid sensing ion channel 1a in the brain of a mouse model of phenylketonuria. Int J Neurosci 121(7):399–404CrossRefPubMed
go back to reference Liappis N, Pohl B, Weber HP, el-Karkani H (1986) Free amino acids in the saliva of children with phenylketonuria. Klin Padiatr 198(1):25–28CrossRefPubMed Liappis N, Pohl B, Weber HP, el-Karkani H (1986) Free amino acids in the saliva of children with phenylketonuria. Klin Padiatr 198(1):25–28CrossRefPubMed
go back to reference Martynyuk AE, Glushakov AV, Sumners C, Laipis PJ, Dennis DM, Seubert CN (2005) Impaired glutamatergic synaptic transmission in the PKU brain. Mol Genet Metab 86(Suppl 1):S34–S42CrossRefPubMed Martynyuk AE, Glushakov AV, Sumners C, Laipis PJ, Dennis DM, Seubert CN (2005) Impaired glutamatergic synaptic transmission in the PKU brain. Mol Genet Metab 86(Suppl 1):S34–S42CrossRefPubMed
go back to reference Mütze U, Thiele AG, Baerwald C, Ceglarek U, Kiess W, Beblo S (2016) Ten years of specialized adult care for phenylketonuria - a single-centre experience. Orphanet J Rare Dis 11:27CrossRefPubMedPubMedCentral Mütze U, Thiele AG, Baerwald C, Ceglarek U, Kiess W, Beblo S (2016) Ten years of specialized adult care for phenylketonuria - a single-centre experience. Orphanet J Rare Dis 11:27CrossRefPubMedPubMedCentral
go back to reference Oja SS, Saransaari P (2015) Open questions concerning taurine with emphasis on the brain. Adv Exp Med Biol 803:409–413CrossRefPubMed Oja SS, Saransaari P (2015) Open questions concerning taurine with emphasis on the brain. Adv Exp Med Biol 803:409–413CrossRefPubMed
go back to reference Sawin EA, Murali SG, Ney DM (2014) Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice. Mol Genet Metab 111:452–461CrossRefPubMedPubMedCentral Sawin EA, Murali SG, Ney DM (2014) Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice. Mol Genet Metab 111:452–461CrossRefPubMedPubMedCentral
go back to reference Schloesser A, Campbell G, Glüer CC, Rimbach G, Huebbe P (2015) Restriction on an energy-dense diet improves markers of metabolic health and cellular aging in mice through decreasing hepatic mTOR activity. Rejuvenation Res 18(1):30–39CrossRefPubMedPubMedCentral Schloesser A, Campbell G, Glüer CC, Rimbach G, Huebbe P (2015) Restriction on an energy-dense diet improves markers of metabolic health and cellular aging in mice through decreasing hepatic mTOR activity. Rejuvenation Res 18(1):30–39CrossRefPubMedPubMedCentral
go back to reference Schreiber JM, Pearl PL, Dustin I, Wiggs E, Barrios E, Wassermann EM, Gibson KM, Theodore WH (2016) Biomarkers in a taurine trial for succinic semialdehyde dehydrogenase deficiency. JIMD Rep. doi:10.1007/8904_2015_524 Schreiber JM, Pearl PL, Dustin I, Wiggs E, Barrios E, Wassermann EM, Gibson KM, Theodore WH (2016) Biomarkers in a taurine trial for succinic semialdehyde dehydrogenase deficiency. JIMD Rep. doi:10.​1007/​8904_​2015_​524
go back to reference Sharman R, Sullivan K, Young R, McGill J (2015) Executive function in adolescents with PKU and their siblings: associations with biochemistry. Mol Genet Metab Rep 4:87–88CrossRefPubMedPubMedCentral Sharman R, Sullivan K, Young R, McGill J (2015) Executive function in adolescents with PKU and their siblings: associations with biochemistry. Mol Genet Metab Rep 4:87–88CrossRefPubMedPubMedCentral
go back to reference Trefz FK, van Spronsen FJ, MacDonald A, Feillet F, Muntau AC, Belanger-Quintana A, Burlina A, Demirkol M, Giovannini M, Gasteyger C (2015) Management of adult patients with phenylketonuria: survey results from 24 countries. Eur J Pediatr 174(1):119–127CrossRefPubMed Trefz FK, van Spronsen FJ, MacDonald A, Feillet F, Muntau AC, Belanger-Quintana A, Burlina A, Demirkol M, Giovannini M, Gasteyger C (2015) Management of adult patients with phenylketonuria: survey results from 24 countries. Eur J Pediatr 174(1):119–127CrossRefPubMed
go back to reference van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de Blaauw P, Kema IP, Heiner-Fokkema MR, van Anholt RD, van der Zee EA, van Spronsen FJ (2015) Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE 10(12):e0143833CrossRefPubMedPubMedCentral van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de Blaauw P, Kema IP, Heiner-Fokkema MR, van Anholt RD, van der Zee EA, van Spronsen FJ (2015) Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE 10(12):e0143833CrossRefPubMedPubMedCentral
go back to reference Vogel KR, Arning E, Wasek BL, Bottiglieri T, Gibson KM (2013a) Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood–brain phenylalanine transport in Pah enu2 mice: preliminary findings. Mol Genet Metab 110(Suppl):S71–S78CrossRefPubMedPubMedCentral Vogel KR, Arning E, Wasek BL, Bottiglieri T, Gibson KM (2013a) Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood–brain phenylalanine transport in Pah enu2 mice: preliminary findings. Mol Genet Metab 110(Suppl):S71–S78CrossRefPubMedPubMedCentral
go back to reference Vogel KR, Arning E, Wasek BL, Bottiglieri T, Gibson KM (2013b) Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice. J Inherit Metab Dis 36(3):513–523CrossRefPubMed Vogel KR, Arning E, Wasek BL, Bottiglieri T, Gibson KM (2013b) Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice. J Inherit Metab Dis 36(3):513–523CrossRefPubMed
go back to reference Vogel KR, Ainslie GR, Phillips B, Arning E, Bottiglieri T, Shen DD, Gibson KM (2015) Physiological competition of brain phenylalanine accretion: initial pharmacokinetic analyses of aminoisobutyric and methylaminoisobutyric acids in Pahenu2−/− mice. Mol Genet Metab Rep 3:80–87CrossRefPubMedPubMedCentral Vogel KR, Ainslie GR, Phillips B, Arning E, Bottiglieri T, Shen DD, Gibson KM (2015) Physiological competition of brain phenylalanine accretion: initial pharmacokinetic analyses of aminoisobutyric and methylaminoisobutyric acids in Pahenu2−/− mice. Mol Genet Metab Rep 3:80–87CrossRefPubMedPubMedCentral
go back to reference Wesonga E, Shimony JS, Rutlin J, Grange DK, White DA (2016) Relationship between age and white matter integrity in children with phenylketonuria. Mol Genet Metab Rep 7:45–49CrossRefPubMedPubMedCentral Wesonga E, Shimony JS, Rutlin J, Grange DK, White DA (2016) Relationship between age and white matter integrity in children with phenylketonuria. Mol Genet Metab Rep 7:45–49CrossRefPubMedPubMedCentral
go back to reference Yano S, Moseley K, Fu X, Azen C (2016) Evaluation of tetrahydrobiopterin therapy with large neutral amino acid supplementation in phenylketonuria: effects on potential peripheral biomarkers, melatonin and dopamine, for brain monoamine neurotransmitters. PLoS ONE 11(8):e0160892CrossRefPubMedPubMedCentral Yano S, Moseley K, Fu X, Azen C (2016) Evaluation of tetrahydrobiopterin therapy with large neutral amino acid supplementation in phenylketonuria: effects on potential peripheral biomarkers, melatonin and dopamine, for brain monoamine neurotransmitters. PLoS ONE 11(8):e0160892CrossRefPubMedPubMedCentral
Metadata
Title
Multicompartment analysis of protein-restricted phenylketonuric mice reveals amino acid imbalances in brain
Authors
Kara R. Vogel
Erland Arning
Teodoro Bottiglieri
K. Michael Gibson
Publication date
01-03-2017
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9984-3

Other articles of this Issue 2/2017

Journal of Inherited Metabolic Disease 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.